EyePoint Pharmaceuticals, Inc. (EYPT Quick QuoteEYPT - Free Report) was a big mover last session, as the company saw its shares rise nearly 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $2.34 –$3.77 in the past one-month time frame, witnessed a sharp increase yesterday.

The stock gained after the company announced that its YUTIQ (fluocinolone acetonide intravitreal implant), which is used for the treatment of chronic non-infectious uveitis, received FDA approval.

The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

EyePoint Pharmaceuticals currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.

Investors interested in the Medical - Biomedical and Genetics industry may consider a better-ranked stock like Vascular Biogenics Ltd. , which carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is EYPT going up? Or down? Predict to see what others think:Up or Down

The Hottest Tech Mega-Trend of All

Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>